Literature DB >> 27621326

Evolution of the Management of Resectable Pancreatic Cancer.

Susan Tsai1, Beth A Erickson2, Kulwinder Dua2, Paul S Ritch2, Parag Tolat2, Douglas B Evans2.   

Abstract

In pancreatic cancer, as with many other solid tumors, a commonly held surgical adage-a chance to cut is a chance to cure-has been promulgated throughout the years. Following such reasoning, surgical extirpation of a localized tumor would prevent tumor dissemination and metastatic tumor progression. However, decades of surgical experience have demonstrated that surgical resection alone provides a limited median survival benefit. Despite the optimization of surgical technique and perioperative management over the past three decades, little progress has been made to improve the limited survival of patients with localized pancreatic cancer who receive surgery. In this article, we discuss the rationale for a novel management strategy for patients with resectable pancreatic cancer, which may improve patient selection and the delivery of multimodality therapy.
Copyright © 2016 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2016        PMID: 27621326     DOI: 10.1200/JOP.2016.015818

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  8 in total

1.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

2.  Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?

Authors:  Chad A Barnes; Ashley N Krepline; Mohammed Aldakkak; Callisia N Clarke; Kathleen K Christians; Abdul H Khan; Bryan C Hunt; Paul S Ritch; Ben George; William A Hall; Beth A Erickson; Douglas B Evans; Susan Tsai
Journal:  J Gastrointest Surg       Date:  2017-08-28       Impact factor: 3.452

3.  Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology program.

Authors:  Jonathan S Bleeker; Christopher J Sumey; Steven F Powell; Preston D Steen; Michael D Keppen; Michele Lohr; Thavam Thambi-Pillai; Peter Kurniali; Miroslaw Mazurczak; Mark M Gitau; Miran J Blanchard; Ryan K Nowak; Steven McGraw; Robert Sticca; Daniel Tuvin; Gary Timmerman
Journal:  Surg Open Sci       Date:  2020-07-29

4.  Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer.

Authors:  David Wittmann; William A Hall; Kathleen K Christians; Chad A Barnes; Neil R Jariwalla; Mohammed Aldakkak; Callisia N Clarke; Ben George; Paul S Ritch; Matthew Riese; Abdul H Khan; Naveen Kulkarni; John Evans; Beth A Erickson; Douglas B Evans; Susan Tsai
Journal:  Front Oncol       Date:  2020-04-15       Impact factor: 6.244

5.  Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.

Authors:  Liang Liang; Ying Ding; Yiyi Yu; Kai Liu; Shengxiang Rao; Yingqian Ge; Mengsu Zeng
Journal:  BMC Med Imaging       Date:  2021-04-26       Impact factor: 1.930

6.  S100A4 overexpression in pancreatic ductal adenocarcinoma: imaging biomarkers from whole-tumor evaluation with MRI and texture analysis.

Authors:  Liang Liang; Rongkui Luo; Ying Ding; Kai Liu; Licheng Shen; Haiying Zeng; Yingqian Ge; Mengsu Zeng
Journal:  Abdom Radiol (NY)       Date:  2020-08-01

7.  The resectable pancreatic ductal adenocarcinoma: To FNA or not to FNA? A diagnostic dilemma, FNA pros.

Authors:  Maria Chiara Petrone; Livia Archibugi
Journal:  Endosc Ultrasound       Date:  2017-12       Impact factor: 5.628

8.  Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer.

Authors:  Yang Chen; Li Wang; Shi Luo; Jun Hu; Xing Huang; Pei-Wen Li; Yi Zhang; Chao Wu; Bo-Le Tian
Journal:  Drug Des Devel Ther       Date:  2020-07-23       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.